Autres langues Theravance Biopharma, Inc.

Actions

TBPH

KYG8807B1068

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
8,44 ^USD	-6,12%		-8,46%	-24,91%

12/04	Mise à jour sectorielle : Les actions du secteur de la santé en baisse vendredi après-midi	MT
12/04	Les actions de Theravance Biopharma augmentent après que BTIG ait commencé sa couverture avec une note d'achat	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024	29/04
Sector Update: Health Care Stocks Lower Friday Afternoon	12/04
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	12/04
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024	10/04
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	01/03
Theravance Bio: Q4 Earnings Snapshot	26/02
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M	26/02
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26/02
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Theravance Biopharma to Participate in an Upcoming Investor Conference	22/02
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	14/02
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint	05/01
Top Premarket Decliners	05/01
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)	05/01
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease	05/01
Theravance Biopharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed.	01/01
Theravance Biopharma : Material Event - Form 8-K	28/12
Theravance Biopharma Announces Appointment of Jeremy Grant to Board of Directors	21/12
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director	21/12
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors	21/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Theravance Biopharma, Inc.

Actions

TBPH

KYG8807B1068

Autres langues

Filtres